Literature DB >> 24136332

Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial.

Prescott G Woodruff1, Wissam Chatila, John E Connett, Gerard J Criner, Jeffrey L Curtis, Mark T Dransfield, Meilan K Han, Stephen C Lazarus, Nathaniel Marchetti, Thomas J Rogers, Paul D Scanlon, Don D Sin, Helen Voelker, Christine Wendt, Richard K Albert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24136332      PMCID： PMC4326242          DOI： 10.1183/09031936.00140613

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  10 in total

1.  Soluble tumor necrosis factor receptors are elevated in relation to severity of congestive heart failure.

Authors:  N Nozaki; S Yamaguchi; M Shirakabe; H Nakamura; H Tomoike
Journal:  Jpn Circ J       Date:  1997-08

2.  Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.

Authors:  Dennis E Niewoehner; Kathryn Rice; Claudia Cote; Daniel Paulson; J Allen D Cooper; Larry Korducki; Cara Cassino; Steven Kesten
Journal:  Ann Intern Med       Date:  2005-09-06       Impact factor: 25.391

3.  Azithromycin for prevention of exacerbations of COPD.

Authors:  Richard K Albert; John Connett; William C Bailey; Richard Casaburi; J Allen D Cooper; Gerard J Criner; Jeffrey L Curtis; Mark T Dransfield; Meilan K Han; Stephen C Lazarus; Barry Make; Nathaniel Marchetti; Fernando J Martinez; Nancy E Madinger; Charlene McEvoy; Dennis E Niewoehner; Janos Porsasz; Connie S Price; John Reilly; Paul D Scanlon; Frank C Sciurba; Steven M Scharf; George R Washko; Prescott G Woodruff; Nicholas R Anthonisen
Journal:  N Engl J Med       Date:  2011-08-25       Impact factor: 91.245

Review 4.  Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NF-kappaB.

Authors:  B B Aggarwal
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

5.  The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease.

Authors:  N Takabatake; H Nakamura; S Abe; S Inoue; T Hino; H Saito; H Yuki; S Kato; H Tomoike
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

6.  Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease.

Authors:  E Osika; J M Cavaillon; K Chadelat; M Boule; C Fitting; G Tournier; A Clement
Journal:  Eur Respir J       Date:  1999-08       Impact factor: 16.671

7.  Longitudinal follow-up of systemic inflammation after acute exacerbations of COPD.

Authors:  Karin H Groenewegen; Mieke A Dentener; Emiel F M Wouters
Journal:  Respir Med       Date:  2007-07-20       Impact factor: 3.415

8.  Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors.

Authors:  D Aderka; H Engelmann; Y Maor; C Brakebusch; D Wallach
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

Review 9.  The possible role of tumor necrosis factor (TNF) and its natural inhibitors, the soluble-TNF receptors, in autoimmune diseases.

Authors:  D Aderka; H Engelmann; A J Wysenbeek; Y Levo
Journal:  Isr J Med Sci       Date:  1992-02

10.  Differential expression of TNFR1 (CD120a) and TNFR2 (CD120b) on subpopulations of human monocytes.

Authors:  Daniëlle Hijdra; Adriane Dm Vorselaars; Jan C Grutters; Anke Me Claessen; Ger T Rijkers
Journal:  J Inflamm (Lond)       Date:  2012-10-05       Impact factor: 4.981
  10 in total
  4 in total

Review 1.  Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management.

Authors:  Prescott G Woodruff; Alvar Agusti; Nicolas Roche; Dave Singh; Fernando J Martinez
Journal:  Lancet       Date:  2015-05-02       Impact factor: 79.321

Review 2.  Anti-TNFα therapy in inflammatory lung diseases.

Authors:  Rama Malaviya; Jeffrey D Laskin; Debra L Laskin
Journal:  Pharmacol Ther       Date:  2017-06-19       Impact factor: 12.310

3.  Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori.

Authors:  Seung Won Ra; Marc A Sze; Eun Chong Lee; Sheena Tam; Yeni Oh; Nick Fishbane; Gerard J Criner; Prescott G Woodruff; Stephen C Lazarus; Richard Albert; John E Connett; Meilan K Han; Fernando J Martinez; Shawn D Aaron; Robert M Reed; S F Paul Man; Don D Sin
Journal:  Respir Res       Date:  2017-05-30

4.  Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).

Authors:  Samantha C Herath; Rebecca Normansell; Samantha Maisey; Phillippa Poole
Journal:  Cochrane Database Syst Rev       Date:  2018-10-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.